ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Alpharma, Fort Lee, N.J., has agreed to sell its generic drug business to the Icelandic generics firm Actavis Group for $810 million. Alpharma will retain its branded pharmaceuticals, active pharmaceutical ingredients, and animal health businesses. Actavis, which earlier this year acquired Amide Pharmaceuticals, another New Jersey-based firm, for $570 million, will gain a significant U.S. business in generics as well as a line of branded over-the-counter skin care products in Europe. Actavis claims the purchase will place it among the top five global generics players, with a portfolio of more than 600 products and an additional 200-plus candidates in its pipeline. Alpharma CEO Ingrid Wiik says the divestiture “will concentrate our focus on our specialty pharmaceutical businesses, simplify our organization, and provide significantly improved financial capacity.” According to Alpharma, 56% of its generics sales of $446 million in the first half of 2005 were in the U.S. Actavis is projecting 2006 sales of $1.6 billion.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter